Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

Wei Wei; Ning Li; Yangchun Sun; Bin Li; Lily Xu; Lingying Wu

doi:10.18632/oncotarget.13317

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

Wei Wei _, Ning Li, Yangchun Sun, Bin Li, Lily Xu and Lingying Wu

PDF | HTML | How to cite

Oncotarget. 2017; 8:23862-23870. https://doi.org/10.18632/oncotarget.13317

Metrics: PDF 1531 views | HTML 2871 views | ?

Abstract

Wei Wei1, Ning Li1, Yangchun Sun1, Bin Li1, Lily Xu2 and Lingying Wu1

1 Department of Gynecologic Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2 Chemistry Department, Wellesley College, Wellesley, MA, USA

Correspondence to:

Lingying Wu, email:

Keywords: ovarian cancer, early-stage, prognosis, survival, recurrence

Received: September 09, 2016 Accepted: October 14, 2016 Published: November 11, 2016

Abstract

Some subsets of early stage ovarian cancer patients experience more recurrences than others. Studies on prognostics factors gave conflicting results. We investigated consecutive 221 patients with stage I/II ovarian cancer at our institution from 1999 to 2010. Univariate and multivariate analysis of progression free survival (PFS) and overall survival (OS) were performed. After a median follow-up of 79 months, the 5-year/10-year PFS and 5-year/10-year OS were 78% /76% and 90% /87% respectively. Multivariate analysis revealed that stage as the most prominent independent prognostic factor in terms of PFS (stage I vs stage IIA vs stage IIB, Hazard Ratio (HR): 1 vs 4 vs 6.1, P < 0.05) and OS (stage I vs stage II, HR: 1 vs 2.1, P < 0.05). Peritoneal biopsy reduced the risk of recurrence by 29% (95% CI: 0.15-0.58, P < 0.05). Ascites (HR = 2.8, 95% CI: 1.2-6.6, P < 0.05) and not the first-line chemotherapy (HR = 2.6, 95% CI: 1.1-6.5, P < 0.05) contributed to decreased OS. Overall, early-stage ovarian cancer had a favorable outcome, stage was the most powerful prognostic factor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13317

Publication Alerts

Clinical Research Papers:

Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

Abstract